CymaBay Therapeutics, Inc. (CBAY) Cash flow
Market cap
$3.7B
P/E ratio
| 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Stock-based compensation | 1 | 1 | 2 | 2 | 5 | 7 | 10 | 7 | 10 | 10 | 15 |
| Cash from operations | -8 | -21 | -23 | -23 | -20 | -55 | -98 | -45 | -69 | -84 | -72 |
| Capital expenditures | - | -0 | - | -0 | -0 | -1 | -0 | -0 | -0 | -0 | -0 |
| Cash from investing | -6 | -17 | -11 | 27 | -68 | -54 | -34 | 48 | 49 | -46 | -87 |
| Cash from financing | 31 | 25 | 31 | -1 | 100 | 135 | 108 | 0 | 118 | 25 | 346 |
| Free cash flow | - | - | |||||||||
| FCF margin (%) | - | - | - | - | - | - | - | - | - | - |